Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs TransMedics Group Inc — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $93.31, while TransMedics Group Inc trades at $73.5 (market cap $2.54B). Which is the better fit depends on your goals.
| IEF | TMDX | |
|---|---|---|
52-Week High | $97.99 | $150.42 |
52-Week Low | $93.11 | $61.99 |
Market Cap | — | $2.54B |
Sector | — | Technology |
Enterprise Value | — | $2.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF trades at $93.31, down 0.56% on the day amid a bearish technical outlook with moving averages signaling sell pressure. Recent dividends of $0.31-$0.32 per share reflect income stability, while news highlights bond ETF competition and Federal Reserve uncertainty. The asset faces headwinds from rising rate hike expectations and inflation concerns, with technical indicators showing neutral oscillators but bearish trend strength.
The outlook for IEF remains cautious due to potential Fed tightening and bond market volatility. Investment appeal hinges on income generation from dividends, but risks include interest rate sensitivity and macroeconomic shifts. Investors should weigh yield advantages against duration risk in a fluctuating rate environment.
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
